Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
AKBA Stock Chart & Stats
$1.36
$0.30(14.49%)
At close: 4:00 PM EST
$1.36
$0.30(14.49%)
Day’s Range― - ―
52-Week Range$1.31 - $4.08
Previous CloseN/A
Volume5.66M
Average Volume (3M)2.85M
Market Cap
$360.90M
Enterprise Value$794.19M
Total Cash (Recent Filing)$166.44M
Total Debt (Recent Filing)$52.58M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 12, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding265,366,000
10 Day Avg. Volume3,374,313
30 Day Avg. Volume2,854,655
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)-8.15
Price to Sales (P/S)2.50
P/FCF Ratio-9.85
Enterprise Value/Market Cap2.20
Enterprise Value/Revenue3.53
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda37.41
Forecast
1Y Price Target
$5.67Price Target Upside316.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.12
Revenue Forecast (FY)$293.02M
Bulls Say, Bears Say
Bulls Say
Dialysis Commercial AccessEstablished supply agreements with major dialysis providers and a strategic push to position VAFSEO as an oral standard-of-care increase potential patient access and commercial opportunity in the dialysis anemia market.
Pipeline ExpansionInitiation of a Phase 2 trial for praliciguat and the acquisition of AKB-097 broaden the renal pipeline, offering potential new therapeutic avenues beyond current products.
Post-marketing Convenience StudiesOngoing post-marketing studies evaluating less-frequent dosing for VAFSEO aim to improve prescribing convenience and patient compliance, which could strengthen clinician preference and uptake.
Bears Say
Efficacy UncertaintyMixed results in prior trials, including a failure to meet a primary endpoint in one study, create uncertainty about the therapy's clinical benefit in certain indications.
Market Opportunity LossDecision not to pursue the Phase 3 VALOR trial removes access to the CKD non-dialysis segment, eliminating a substantial commercial market opportunity.
Patient Adherence RiskConcerns about patient adherence at the first refill after initial prescription could limit long-term treatment persistence and reduce expected uptake of VAFSEO.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $1.31 and its highest was $4.08 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $360.90M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 52 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Nov 10, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.011 by $0.011.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is <0.01.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 265,366,000 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.011. Following the earnings report the stock price went down -18.137%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (316.91% Upside)
$5.67 (316.91% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 806.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.80%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of strong prescription growth and financial improvements, offset by operational and adherence challenges impacting Vafseo's rollout. While revenue and patient access have grown significantly, the company faces hurdles in addressing logistics and adherence issues to sustain this growth.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$5.67
▲(316.91% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.26% Insiders
9.38% Mutual Funds
0.06% Other Institutional Investors
73.54% Public Companies and Individual Investors